Allergan (NYSE:AGN)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork.com reports. They currently have a $97.00 price target on the stock. Zacks‘ price objective would indicate a potential upside of 4.65% from the company’s current price.
Allergan (NYSE:AGN) traded down 0.50% during mid-day trading on Wednesday, hitting $92.23. 772,184 shares of the company’s stock traded hands. Allergan has a 1-year low of $81.33 and a 1-year high of $116.45. The stock has a 50-day moving average of $89.87 and a 200-day moving average of $99.37. The company has a market cap of $27.379 billion and a P/E ratio of 29.81.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $1.23 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.20 by $0.03. The company had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the company posted $1.06 earnings per share. The company’s quarterly revenue was up 13.3% on a year-over-year basis. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on AGN. Analysts at JMP Securities reiterated an “outperform” rating on shares of Allergan in a research note to investors on Thursday, October 17th. Separately, analysts at Credit Suisse initiated coverage on shares of Allergan in a research note to investors on Tuesday, October 8th. They set an “outperform” rating on the stock. Eleven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Allergan presently has a consensus rating of “Buy” and an average price target of $107.22.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.